{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T09:04:00Z","timestamp":1781687040741,"version":"3.54.5"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ejca.2026.116223","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:22:43Z","timestamp":1767831763000},"page":"116223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Precision oncology promise in the management of pancreatic acinar cell carcinoma"],"prefix":"10.1016","volume":"234","author":[{"given":"Suriya","family":"Baskar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T.","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon E.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sawyer","family":"Bawek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Vadehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2089-8236","authenticated-orcid":false,"given":"Nicholas J.","family":"Hornstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udhayvir S.","family":"Grewal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ejca.2026.116223_bib1","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1002\/bjs.4794","article-title":"Current standards of surgery for pancreatic cancer","volume":"91","author":"Alexakis","year":"2004","journal-title":"Br J Surg"},{"issue":"6","key":"10.1016\/j.ejca.2026.116223_bib2","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1053\/j.semdp.2014.08.003","article-title":"Pathology and genetics of pancreatic neoplasms with acinar differentiation","volume":"31","author":"Wood","year":"2014","journal-title":"Semin Diagn Pathol"},{"issue":"9","key":"10.1016\/j.ejca.2026.116223_bib3","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/00000478-199209000-00001","article-title":"Acinar cell carcinoma of the pancreas. A clinicopathologic study of 28 cases","volume":"16","author":"Klimstra","year":"1992","journal-title":"Am J Surg Pathol"},{"issue":"40","key":"10.1016\/j.ejca.2026.116223_bib4","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.3748\/wjg.v28.i40.5827","article-title":"Pancreatic acinar cell carcinoma: A comprehensive review","volume":"28","author":"Calimano-Ramirez","year":"2022","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10.1016\/j.ejca.2026.116223_bib5","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/jjco\/hyad176","article-title":"Comprehensive review of pancreatic acinar cell carcinoma: epidemiology, diagnosis, molecular features and treatment","volume":"54","author":"Ikezawa","year":"2023","journal-title":"Jpn J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2026.116223_bib6","doi-asserted-by":"crossref","DOI":"10.1200\/PO-24-00450","article-title":"Clinical outcomes and molecular profiling of pancreatic acinar cell carcinoma: a retrospective study","author":"Eslinger","year":"2025","journal-title":"JCO Precis Oncol"},{"issue":"45","key":"10.1016\/j.ejca.2026.116223_bib7","doi-asserted-by":"crossref","first-page":"7945","DOI":"10.3748\/wjg.v23.i45.7945","article-title":"Pancreatic acinar cell carcinoma: a review on molecular profiling of patient tumors","volume":"23","author":"Al-Hader","year":"2017","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116223_bib8","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/annonc\/mdx707","article-title":"The European Society for Medical Oncology (ESMO) Precision Medicine Glossary","volume":"29","author":"Yates","year":"2018","journal-title":"Ann Oncol"},{"issue":"37","key":"10.1016\/j.ejca.2026.116223_bib9","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1200\/EDBK_174176","article-title":"Precision oncology: who, how, what, when, and when not?","author":"Schwartzberg","year":"2017","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"17","key":"10.1016\/j.ejca.2026.116223_bib10","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1158\/1078-0432.CCR-22-3724","article-title":"Comparative genomic analysis of pancreatic acinar cell carcinoma (PACC) and pancreatic ductal adenocarcinoma (PDAC) unveils new actionable genomic aberrations in PACC","volume":"29","author":"Florou","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ejca.2026.116223_bib11","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00535-023-01986-9","article-title":"Genomic landscape and clinical features of rare subtypes of pancreatic cancer: analysis with the national database of Japan","volume":"58","author":"Sakakida","year":"2023","journal-title":"J Gastroenterol"},{"issue":"3","key":"10.1016\/j.ejca.2026.116223_bib12","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0002-9440(10)64917-6","article-title":"Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma: frequent allelic loss on chromosome 11p and alterations in the APC\/beta-catenin pathway","volume":"160","author":"Abraham","year":"2002","journal-title":"Am J Pathol"},{"issue":"12","key":"10.1016\/j.ejca.2026.116223_bib13","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1097\/PAS.0b013e318263209d","article-title":"Clinicopathologic study of 62 acinar cell carcinomas of the pancreas: insights into the morphology and immunophenotype and search for prognostic markers","volume":"36","author":"La Rosa","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ejca.2026.116223_bib14","doi-asserted-by":"crossref","first-page":"8829","DOI":"10.1038\/srep08829","article-title":"Whole exome sequencing reveals recurrent mutations in BRCA2 and FAT genes in acinar cell carcinomas of the pancreas","volume":"5","author":"Furukawa","year":"2015","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.ejca.2026.116223_bib15","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.trecan.2024.01.009","article-title":"Fusion genes in pancreatic tumors","volume":"10","author":"Gkountakos","year":"2024","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2026.116223_bib16","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/s41467-019-09374-9","article-title":"Diagnosis of fusion genes using targeted RNA sequencing","volume":"10","author":"Heyer","year":"2019","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.ejca.2026.116223_bib17","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S1470-2045(20)30074-7","article-title":"Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial","volume":"21","author":"Pishvaian","year":"2020","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2026.116223_bib18","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1158\/2159-8290.CD-14-0617","article-title":"Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes","volume":"4","author":"Chmielecki","year":"2014","journal-title":"Cancer Discov"},{"issue":"9","key":"10.1016\/j.ejca.2026.116223_bib19","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1038\/s41379-020-0545-9","article-title":"RAF1 rearrangements are common in pancreatic acinar cell carcinomas","volume":"33","author":"Prall","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ejca.2026.116223_bib20","article-title":"Whole genome and transcriptome analysis of pancreatic acinar cell carcinoma elucidates mechanisms of homologous recombination deficiency and unravels novel relevant fusion events","volume":"266","author":"Delgado-de la Mora","year":"2025","journal-title":"Pathol Res Pr"},{"issue":"4","key":"10.1016\/j.ejca.2026.116223_bib21","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41379-019-0373-y","article-title":"RET gene rearrangements occur in a subset of pancreatic acinar cell carcinomas","volume":"33","author":"Chou","year":"2020","journal-title":"Mod Pathol"},{"issue":"19","key":"10.1016\/j.ejca.2026.116223_bib22","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.3390\/cancers16193421","article-title":"Molecular and clinical features of pancreatic acinar cell carcinoma: a single-institution case series","volume":"16","author":"Balachandran Pillai","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejca.2026.116223_bib23","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3389\/fmolb.2020.00024","article-title":"Studying DNA double-strand break repair: an ever-growing toolbox","volume":"7","author":"V\u00edtor","year":"2020","journal-title":"Front Mol Biosci"},{"issue":"3","key":"10.1016\/j.ejca.2026.116223_bib24","doi-asserted-by":"crossref","first-page":"396","DOI":"10.20892\/j.issn.2095-3941.2019.0097","article-title":"Tissue specificity of DNA damage response and tumorigenesis","volume":"16","author":"Sun","year":"2019","journal-title":"Cancer Biol Med"},{"issue":"33","key":"10.1016\/j.ejca.2026.116223_bib25","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.1200\/JCO.23.00561","article-title":"Genomic profiling reveals germline predisposition and homologous recombination deficiency in pancreatic acinar cell carcinoma","volume":"41","author":"Mandelker","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2026.116223_bib26","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s10689-024-00390-3","article-title":"The response of pancreatic acinar cell carcinoma to platinum and olaparib therapy in a germline BRCA2 variant carrier: case report and literature review","volume":"23","author":"Matsubayashi","year":"2024","journal-title":"Fam Cancer"},{"issue":"12","key":"10.1016\/j.ejca.2026.116223_bib27","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.6718","article-title":"Prolonged response on olaparib maintenance in metastatic pancreatic acinar cell carcinoma associated with a germline BRCA2 mutation, revealed by severe panniculitis","volume":"10","author":"Lelong","year":"2022","journal-title":"Clin Case Rep"},{"issue":"45","key":"10.1016\/j.ejca.2026.116223_bib28","doi-asserted-by":"crossref","first-page":"6421","DOI":"10.3748\/wjg.v28.i45.6421","article-title":"Germline BRCA2 variants in advanced pancreatic acinar cell carcinoma: A case report and review of literature","volume":"28","author":"Lee","year":"2022","journal-title":"World J Gastroenterol"},{"issue":"45","key":"10.1016\/j.ejca.2026.116223_bib29","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000013113","article-title":"Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib: a case report","volume":"97","author":"Li","year":"2018","journal-title":"Med (Baltim)"},{"issue":"4","key":"10.1016\/j.ejca.2026.116223_bib30","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s12328-024-01981-4","article-title":"Long-term survival after systemic chemotherapy, chemoradiotherapy, and maintenance therapy for an older adult patient with recurrent pancreatic acinar cell carcinoma","volume":"17","author":"Urabe","year":"2024","journal-title":"Clin J Gastroenterol"},{"issue":"5","key":"10.1016\/j.ejca.2026.116223_bib31","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1159\/000515267","article-title":"Pancreatic acinar cell carcinoma with germline BRCA2 mutation and severe pancreatic panniculitis: a case report","volume":"37","author":"Dreikhausen","year":"2021","journal-title":"Visc Med"},{"issue":"8","key":"10.1016\/j.ejca.2026.116223_bib32","article-title":"Germline BRCA1-mutated synchronous and metachronous pancreatic acinar cell carcinoma with long-term survival","volume":"7","author":"Kubo","year":"2024","journal-title":"Cancer Rep (Hoboken)"},{"key":"10.1016\/j.ejca.2026.116223_bib33","doi-asserted-by":"crossref","first-page":"TPS789","DOI":"10.1200\/JCO.2025.43.4_suppl.TPS789","article-title":"Phase II study of olaparib in patients with advanced pancreatic acinar cell carcinoma","volume":"43","author":"Skorupan","year":"2025","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2026.116223_bib34","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1038\/s12276-022-00864-3","article-title":"Molecular targeted therapy for anticancer treatment","volume":"54","author":"Min","year":"2022","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.ejca.2026.116223_bib35","unstructured":"U.S. Food and Drug Administration. FDA grants accelerated approval to dabrafenib in combination with trametinib for unresectable or metastatic solid tumors with BRAF V600E mutation. Published 2022. Accessed April 12, 2025. \u3008https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid\u3009."},{"issue":"4","key":"10.1016\/j.ejca.2026.116223_bib36","doi-asserted-by":"crossref","DOI":"10.1101\/mcs.a005553","article-title":"Successful BRAF\/MEK inhibition in a patient with BRAF(V600E)-mutated extrapancreatic acinar cell carcinoma","volume":"6","author":"Busch","year":"2020","journal-title":"Cold Spring Harb Mol Case Stud"},{"issue":"4","key":"10.1016\/j.ejca.2026.116223_bib37","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1200\/PO.19.00343","article-title":"Pediatric BRAF (V600E)-mutated pancreatic acinar cell carcinoma with complete and durable response to dabrafenib and trametinib","author":"Cramer","year":"2020","journal-title":"JCO Precis Oncol"},{"issue":"17","key":"10.1016\/j.ejca.2026.116223_bib38","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1158\/1078-0432.CCR-22-3724","article-title":"Comparative genomic analysis of pancreatic acinar cell carcinoma (PACC) and pancreatic ductal adenocarcinoma (PDAC) unveils new actionable genomic aberrations in PACC","volume":"29","author":"Florou","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.ejca.2026.116223_bib39","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116223_bib40","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41698-021-00206-y","article-title":"Genomic context of NTRK1\/2\/3 fusion-positive tumours from a large real-world population","volume":"5","author":"Westphalen","year":"2021","journal-title":"npj Precis Oncol"},{"issue":"19","key":"10.1016\/j.ejca.2026.116223_bib41","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.3390\/cancers16193395","article-title":"Tissue-AGNOSTIC TARGETING OF NEUROTROPHIC TYROSINE RECEPTOR KINASE FUSIONS: CURRENT APPROVALS AND FUTURE DIREctions","volume":"16","author":"Gouda","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ejca.2026.116223_bib42","doi-asserted-by":"crossref","first-page":"10","DOI":"10.6004\/jnccn.2020.7641","article-title":"Targeting the NTRK FUSION GENE IN PANCREATIC ACINAR CELL CARCINOMA: A CASE REPORT AND REVIEW OF THE LITERature","volume":"19","author":"Gupta","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.ejca.2026.116223_bib43","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41698-024-00497-x","article-title":"Post-therapy emergence of an NBN reversion mutation in a patient with pancreatic acinar cell carcinoma","volume":"8","author":"Pelster","year":"2024","journal-title":"NPJ Precis Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2026.116223_bib44","doi-asserted-by":"crossref","first-page":"NP24","DOI":"10.1177\/0300891620980792","article-title":"Efficacy of chemotherapy combined with toripalimab in PD-L1\u2013positive and high tumor mutation burden pancreatic acinar cell carcinoma: case report","volume":"107","author":"Xu","year":"2021","journal-title":"Tumor J"},{"issue":"4","key":"10.1016\/j.ejca.2026.116223_bib45","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4251\/wjgo.v10.i4.103","article-title":"EGFR amplification induces sensitivity to anti-EGFR therapy in pancreatic acinar cell carcinoma","volume":"10","author":"Richard","year":"2018","journal-title":"World J Gastrointest Oncol"},{"key":"10.1016\/j.ejca.2026.116223_bib46","doi-asserted-by":"crossref","first-page":"142","DOI":"10.7150\/jca.2.142","article-title":"An effective personalized approach to a rare tumor: prolonged survival in metastatic pancreatic acinar cell carcinoma based on genetic analysis and cell line development","volume":"2","author":"Armstrong","year":"2011","journal-title":"J Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2026.116223_bib47","doi-asserted-by":"crossref","DOI":"10.1200\/PO.21.00400","article-title":"Exceptional clinical response to alectinib in pancreatic acinar cell carcinoma with a novel ALK-KANK4 gene fusion","author":"Gaule","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"44","key":"10.1016\/j.ejca.2026.116223_bib48","doi-asserted-by":"crossref","first-page":"16433","DOI":"10.3748\/wjg.v20.i44.16433","article-title":"Causes and consequences of microsatellite instability in gastric carcinogenesis","volume":"20","author":"Velho","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.ejca.2026.116223_bib49","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41571-025-01015-z","article-title":"Epidemiology, pathogenesis, biology and evolving management of MSI-H\/dMMR cancers","volume":"22","author":"Ambrosini","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116223_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity Cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.ejca.2026.116223_bib51","doi-asserted-by":"crossref","DOI":"10.4161\/onci.29288","article-title":"PD-L1 expression and tumor-infiltrating lymphocytes: revisiting the antitumor immune response potential in breast cancer","volume":"3","author":"Schalper","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ejca.2026.116223_bib52","unstructured":"U.S. Food and Drug Administration. FDA grants accelerated approval to pembrolizumab for first tissue\/site agnostic indication. Published 2017. Accessed April 12, 2025. \u3008https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication\u3009."},{"issue":"1","key":"10.1016\/j.ejca.2026.116223_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2026.116223_bib54","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1097\/MPA.0000000000000190","article-title":"DNA mismatch repair abnormalities in acinar cell carcinoma of the pancreas: frequency and clinical significance","volume":"43","author":"Liu","year":"2014","journal-title":"Pancreas"},{"issue":"7","key":"10.1016\/j.ejca.2026.116223_bib55","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00432-024-05841-z","article-title":"Complete pathological response to pembrolizumab in pretreated pancreatic acinar cell carcinoma","volume":"150","author":"Merz","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"issue":"27","key":"10.1016\/j.ejca.2026.116223_bib56","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1200\/JCO.20.01364","article-title":"Metastatic pancreatic cancer: ASCO guideline update","volume":"38","author":"Sohal","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2026.116223_bib57","doi-asserted-by":"crossref","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","article-title":"Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Tempero","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"13","key":"10.1016\/j.ejca.2026.116223_bib58","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.19.02931","article-title":"Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA\/PALB2 mutation","volume":"38","author":"O'Reilly","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2026.116223_bib59","doi-asserted-by":"crossref","first-page":"759","DOI":"10.4143\/crt.2016.371","article-title":"Efficacy of chemotherapy in patients with unresectable or metastatic pancreatic acinar cell carcinoma: potentially improved efficacy with oxaliplatin-containing regimen","volume":"49","author":"Yoo","year":"2017","journal-title":"Cancer Res Treat"},{"issue":"4","key":"10.1016\/j.ejca.2026.116223_bib60","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejca.2026.116223_bib61","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.path.2022.05.004","article-title":"The evolving paradigm of germline testing in pancreatic ductal adenocarcinoma and implications for clinical practice","volume":"15","author":"Mohindroo","year":"2022","journal-title":"Surg Pathol Clin"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926000031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926000031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T08:47:07Z","timestamp":1781686027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926000031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":61,"alternative-id":["S0959804926000031"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116223","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision oncology promise in the management of pancreatic acinar cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116223","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116223"}}